Sevasemten clinical trials
Also written EDG-5506.
How each study uses sevasemten is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the sevasemten studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
7 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Edgewise Therapeutics, Inc. (7)
Studies
Open first, then newest update. How each study uses sevasemten is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Open-Label Extension of EDG-5506 in Participants With Becker Muscular DystrophyEnrolling by invitationPhase 2Edgewise Therapeutics, Inc.NCT06066580Written as Sevasemten
- Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)CompletedPhase 2Edgewise Therapeutics, Inc.NCT05291091Written as Sevasemten 10 mg
- A Study of EDG-5506 in Adult Males With Becker Muscular DystrophyCompletedPhase 1Edgewise Therapeutics, Inc.NCT05160415Written as Sevasemten
- A Study to Evaluate Effect of Verapamil and Food of Sevasemten in Healthy VolunteersCompletedPhase 1Edgewise Therapeutics, Inc.NCT06916897Written as sevasemten
- Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy VolunteersCompletedPhase 1Edgewise Therapeutics, Inc.NCT05730842Written as EDG-5506 Tablet
- A Study to Assess the Feasibility of Non-invasive Dried Blood SamplingCompletedPhase 1Edgewise Therapeutics, Inc.NCT05492734Written as EDG-5506
- A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy AdultsCompletedPhase 1Edgewise Therapeutics, Inc.NCT04585464Written as EDG-5506
Codes
What other systems call sevasemten · ClinicalTrials.gg INT016979
- UNII (FDA) JT5OYR0WUKSEVASEMTENOne source FDA
- NCI Thesaurus C199222SevasemtenOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | JT5OYR0WUK | SEVASEMTEN | One source FDA |
| NCI Thesaurus | C199222 | Sevasemten | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.